{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:55:03Z","timestamp":1785192903815,"version":"3.55.0"},"reference-count":109,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Psilocybin, a naturally occurring psychedelic compound, has garnered renewed scientific interest for its potential in treating psychiatric and neurological disorders. This review systematically examines the latest research on psilocybin\u2019s pharmacokinetics, pharmacodynamics, clinical efficacy, and safety profile. Emerging evidence supports its efficacy in conditions such as major depressive disorder (MDD), treatment-resistant depression (TRD), anxiety, alcohol use disorders (AUD), and cancer-related distress. Despite promising outcomes, significant barriers remain, including methodological constraints, regulatory hurdles, and limited population diversity in clinical trials. Advances in biosynthetic production and optimized psychotherapeutic integration are necessary to ensure scalability and accessibility. Future research should focus on long-term safety, dosing precision, and neurobiological mechanisms to refine its therapeutic applications. This review provides a critical foundation for advancing evidence-based clinical integration of psilocybin.<\/jats:p>","DOI":"10.3390\/ph18040555","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:05:56Z","timestamp":1744200356000},"page":"555","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Emergence of Psilocybin in Psychiatry and Neuroscience"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5637-8729","authenticated-orcid":false,"given":"Hossein","family":"Omidian","sequence":"first","affiliation":[{"name":"Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alborz","family":"Omidian","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Westchester Medical Center, Valhalla, NY 10595, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40262-017-0540-6","article-title":"Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults","volume":"56","author":"Brown","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for depression","volume":"28","author":"Daws","year":"2022","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41386-020-0718-8","article-title":"Me, myself, bye: Regional alterations in glutamate and the experience of ego dissolution with psilocybin","volume":"45","author":"Mason","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Fang, S., Yang, X., and Zhang, W. (2024). Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials. Front. Psychiatry, 15.","DOI":"10.3389\/fpsyt.2024.1359088"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs. Placebo in the Treatment of Adult Patients with Alcohol Use Disorder: A Randomized Clinical Trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/00377686241301923","article-title":"God hasn\u2019t died, it has merely been encapsulated\u2014Psilocybin and ayahuasca in the psychedelic renaissance: Intersections between religion, indigenous cosmologies, spirituality, and science","volume":"71","author":"Scuro","year":"2024","journal-title":"Soc. Compass"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/cpdd.796","article-title":"Exposure-Response Analysis to Assess the Concentration-QTc Relationship of Psilocybin\/Psilocin","volume":"10","author":"Dahmane","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/ijnp\/pyab085","article-title":"Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel-Mediated Cardiotoxicity","volume":"25","author":"Hackl","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e245960","DOI":"10.1001\/jamanetworkopen.2024.5960","article-title":"Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis","volume":"7","author":"Yerubandi","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Aghajanian, S., Shafiee, A., Parvizi Omran, S., Rezaei Nejad, A., Jafarabady, K., Kohandel Gargari, O., Rajai, S., Mohammadi, I., Bahrami Babaheidari, T., and Bakhtiyari, M. (2024). Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials. J. Psychopharmacol., 2698811241287542.","DOI":"10.1177\/02698811241287542"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/cbic.201900358","article-title":"Enzymatic Route toward 6-Methylated Baeocystin and Psilocybin","volume":"20","author":"Fricke","year":"2019","journal-title":"ChemBioChem"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.encep.2020.08.006","article-title":"Ketamine, psilocybin, and rapid acting antidepressant: New promise for psychiatry?","volume":"47","author":"Bottemanne","year":"2021","journal-title":"Encephale"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1176\/appi.ajp.20230682","article-title":"Psilocybin: From Psychiatric Pariah to Perceived Panacea","volume":"182","author":"Fonzo","year":"2025","journal-title":"Am. J. Psychiatry"},{"key":"ref_14","first-page":"230","article-title":"Psilocybin-Assisted Treatment of Depression, Anxiety and Substance use Disorders: Neurobiological Basis and Clinical Application","volume":"92","author":"Lasch","year":"2024","journal-title":"Fortschr. Neurol. Psychiatr."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Munafo, A., Arillotta, D., Mannaioni, G., Schifano, F., Bernardini, R., and Cantarella, G. (2022). Psilocybin for Depression: From Credibility to Feasibility, What\u2019s Missing?. Pharmaceuticals, 16.","DOI":"10.3390\/ph16010068"},{"key":"ref_16","first-page":"50","article-title":"Research on microdosing with psilocybin mushrooms: A reflection paper","volume":"35","year":"2023","journal-title":"Cult. Droga"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1097\/MJT.0000000000001724","article-title":"Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin","volume":"31","author":"Tabaac","year":"2024","journal-title":"Am. J. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jad.2023.01.108","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life","volume":"327","author":"Goodwin","year":"2023","journal-title":"J. Affect. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e2449026","DOI":"10.1001\/jamanetworkopen.2024.49026","article-title":"Psilocybin Therapy for Clinicians with Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial","volume":"7","author":"Back","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Roseman, L., Nutt, D.J., and Carhart-Harris, R.L. (2017). Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00974"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.medj.2024.01.005","article-title":"Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin","volume":"5","author":"Rosenblat","year":"2024","journal-title":"Med"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/02698811231154852","article-title":"Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial","volume":"37","author":"Sloshower","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101809","DOI":"10.1016\/j.eclinm.2022.101809","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"Schindowski","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/cncr.35010","article-title":"Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder","volume":"130","author":"Agrawal","year":"2024","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Spriggs, M.J., Douglass, H.M., Park, R.J., Read, T., Danby, J.L., de Magalhaes, F.J.C., Alderton, K.L., Williams, T.M., Blemings, A., and Lafrance, A. (2021). Study Protocol for \u201cPsilocybin as a Treatment for Anorexia Nervosa: A Pilot Study\u201d. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.735523"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/head.14656","article-title":"CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity","volume":"64","author":"Madsen","year":"2024","journal-title":"Headache"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Whelan, T.P., Daly, E., Puts, N.A., Smith, P., Allison, C., Baron-Cohen, S., Malievskaia, E., Murphy, D.G.M., and McAlonan, G.M. (2024). The \u2018PSILAUT\u2019 protocol: An experimental medicine study of autistic differences in the function of brain serotonin targets of psilocybin. BMC Psychiatry, 24.","DOI":"10.1186\/s12888-024-05768-2"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e068884","DOI":"10.1136\/bmjopen-2022-068884","article-title":"Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD","volume":"13","author":"Davis","year":"2023","journal-title":"BMJ Open"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"DellaCrosse, M., Pleet, M., Morton, E., Ashtari, A., Sakai, K., Woolley, J., and Michalak, E. (2022). \u201cA sense of the bigger picture\u201d: A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0279073"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Nayak, S.M., Jackson, H., Sepeda, N.D., Mathai, D.S., So, S., Yaffe, A., Zaki, H., Brasher, T.J., Lowe, M.X., and Jolly, D.R.P. (2023). Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: Results from a prospective, longitudinal survey. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1199642"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jpsychires.2023.03.031","article-title":"Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder","volume":"161","author":"Schneier","year":"2023","journal-title":"J. Psychiatr. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cpt.2821","article-title":"Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants","volume":"113","author":"Holze","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1093\/brain\/awae136","article-title":"Psilocybin reduces alcohol self-administration via selective left nucleus accumbens activation in rats","volume":"147","author":"Jeanblanc","year":"2024","journal-title":"Brain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1192\/bjo.2022.565","article-title":"Effects of psilocybin versus escitalopram on rumination and thought suppression in depression","volume":"8","author":"Barba","year":"2022","journal-title":"BJPsych Open"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41398-024-03103-7","article-title":"Psilocybin increases optimistic engagement over time: Computational modelling of behaviour in rats","volume":"14","author":"Fisher","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Jungwirth, J., von Rotz, R., Dziobek, I., Vollenweider, F.X., and Preller, K.H. (2024). Psilocybin increases emotional empathy in patients with major depression. Mol. Psychiatry.","DOI":"10.1038\/s41380-024-02875-0"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1089\/jpm.2023.0189","article-title":"Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study","volume":"26","author":"Gramling","year":"2023","journal-title":"J. Palliat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Liu, J., Wang, Y., Xia, K., Wu, J., Zheng, D., Cai, A., Yan, H., and Su, R. (2023). Acute psilocybin increased cortical activities in rats. Front. Neurosci., 17.","DOI":"10.3389\/fnins.2023.1168911"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41398-023-02690-1","article-title":"Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats","volume":"13","author":"Reinwald","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.biopsych.2024.01.002","article-title":"Neural Mechanisms of Resting-State Networks and the Amygdala Underlying the Cognitive and Emotional Effects of Psilocybin","volume":"96","author":"Stoliker","year":"2024","journal-title":"Biol. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00213-017-4754-y","article-title":"Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression","volume":"235","author":"Stroud","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1176\/appi.ajp.20230887","article-title":"Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients with Alcohol Use Disorder: Results from a Double-Blind, Placebo-Controlled Clinical Trial","volume":"182","author":"Pagni","year":"2025","journal-title":"Am. J. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ching, T.H.W., Amoroso, L., Bohner, C., D\u2019Amico, E., Eilbott, J., Entezar, T., Fitzpatrick, M., Fram, G., Grazioplene, R., and Hokanson, J. (2023). Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: Protocol for a randomized, waitlist-controlled trial with blinded ratings. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1278823"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Dougherty, R.F., Clarke, P., Atli, M., Kuc, J., Schlosser, D., Dunlop, B.W., Hellerstein, D.J., Aaronson, S.T., Zisook, S., and Young, A.H. (2023). Psilocybin therapy for treatment resistant depression: Prediction of clinical outcome by natural language processing. Psychopharmacology.","DOI":"10.1007\/s00213-023-06432-5"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/s41380-024-02786-0","article-title":"Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming","volume":"30","author":"Brownstien","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Pagni, B.A., Petridis, P.D., Podrebarac, S.K., Grinband, J., Claus, E.D., and Bogenschutz, M.P. (2024). Psilocybin-induced changes in neural reactivity to alcohol and emotional cues in patients with alcohol use disorder: An fMRI pilot study. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-52967-8"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Sloshower, J., Zeifman, R.J., Guss, J., Krause, R., Safi-Aghdam, H., Pathania, S., Pittman, B., and D\u2019Souza, D.C. (2024). Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: Results from an exploratory placebo-controlled trial. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-58318-x"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Pots, W., and Chakhssi, F. (2022). Psilocybin-Assisted Compassion Focused Therapy for Depression. Front. Psychol., 13.","DOI":"10.3389\/fpsyg.2022.812930"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcbs.2019.11.002","article-title":"Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame","volume":"15","author":"Sloshower","year":"2020","journal-title":"J. Context. Behav. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1176\/appi.ajp.20230884","article-title":"Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions","volume":"182","author":"Kirlic","year":"2025","journal-title":"Am. J. Psychiatry"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Levin, A.W., Lancelotta, R., Sepeda, N.D., Gukasyan, N., Nayak, S., Wagener, T.L., Barrett, F.S., Griffiths, R.R., and Davis, A.K. (2024). The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0300501"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Murphy, R., Kettner, H., Zeifman, R., Giribaldi, B., Kartner, L., Martell, J., Read, T., Murphy-Beiner, A., Baker-Jones, M., and Nutt, D. (2021). Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.788155"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Palitsky, R., Maples-Keller, J.L., Peacock, C., Dunlop, B.W., Mletzko, T., Grant, G.H., Raison, C.L., Chao, S., Shub, I., and Mendelbaum-Kweller, M. (2025). A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers. Psychotherapy.","DOI":"10.1037\/pst0000551"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"106976","DOI":"10.1016\/j.cct.2022.106976","article-title":"Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial","volume":"123","author":"Mennenga","year":"2022","journal-title":"Contemp. Clin. Trials"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/0022167817715966","article-title":"Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress","volume":"57","author":"Swift","year":"2017","journal-title":"J. Humanist. Psychol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acsptsci.1c00020","article-title":"Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer","volume":"4","author":"Ross","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1192\/bjo.2024.768","article-title":"Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: Case report and thematic analysis of one participant\u2019s experience","volume":"10","author":"Wahba","year":"2024","journal-title":"BJPsych Open"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Mehtani, N.J., Johnson, M.O., Hendricks, P.S., Mitchell, J., and Anderson, B.T. (2024). Psilocybin-assisted therapy and HIV-related shame. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-68908-4"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/medethics-2020-106070","article-title":"Ethics and ego dissolution: The case of psilocybin","volume":"47","author":"Smith","year":"2020","journal-title":"J. Med. Ethics"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1556\/2054.2021.00167","article-title":"Have Norwegians tried psilocybin, and do they accept it as a medicine?","volume":"5","author":"Jacobsen","year":"2021","journal-title":"J. Psychedelic Stud."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/02698811241257839","article-title":"Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi study","volume":"38","author":"Korthuis","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Breeksema, J.J., Niemeijer, A., Krediet, E., Karsten, T., Kamphuis, J., Vermetten, E., van den Brink, W., and Schoevers, R. (2024). Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: A qualitative study. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-53188-9"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jpsychires.2024.10.009","article-title":"The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression","volume":"180","author":"Marwood","year":"2024","journal-title":"J. Psychiatr. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s44220-024-00331-0","article-title":"Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer","volume":"2","author":"Petridis","year":"2024","journal-title":"Nat. Ment. Health"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Malone, T.C., Mennenga, S.E., Guss, J., Podrebarac, S.K., Owens, L.T., Bossis, A.P., Belser, A.B., Agin-Liebes, G., Bogenschutz, M.P., and Ross, S. (2018). Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00256"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Brett, J., Knock, E., Watson, K., Albert, S., Siefried, K.J., and Guss, J. (2024). Psilocybin-assisted sychotherapy for methamphetamine dependence: A case report involving daily methamphetamine use. Front. Psychiatry, 15.","DOI":"10.3389\/fpsyt.2024.1490907"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/j.pain.0000000000002778","article-title":"Microdosing psilocybin for chronic pain: A case series","volume":"164","author":"Lyes","year":"2023","journal-title":"Pain"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"20451253241264812","DOI":"10.1177\/20451253241264812","article-title":"Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery","volume":"14","author":"VanderZwaag","year":"2024","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up","volume":"235","author":"Bolstridge","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"100538","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study","volume":"27","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Ching, T.H.W., Grazioplene, R., Bohner, C., Kichuk, S.A., DePalmer, G., D\u2019Amico, E., Eilbott, J., Jankovsky, A., Burke, M., and Hokanson, J. (2023). Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: Protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1178529"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Vanderijst, L., Hever, F., Buot, A., Daure, C., Benoit, J., Hanak, C., Veeser, J., Morgieve, M., Campanella, S., and Kornreich, C. (2024). Psilocybin-assisted therapy for severe alcohol use disorder: Protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial. BMC Psychiatry, 24.","DOI":"10.1186\/s12888-024-05502-y"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Bakshi, B., Yerraguntla, S., Armon, C., Barkhaus, P., Bertorini, T., Bowser, R., Breevoort, S., Bromberg, M., Brown, A., and Carter, G.T. (2024). ALSUntangled #77: Psilocybin. Amyotroph. Lateral Scler. Frontotemporal Degener., 1\u20134.","DOI":"10.1080\/21678421.2024.2441274"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/head.14837","article-title":"Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: Results from an open-label phase Ib ascending dose study","volume":"64","author":"Rucker","year":"2024","journal-title":"Headache"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"111163","DOI":"10.1016\/j.mehy.2023.111163","article-title":"Can a single dose of psilocybin improve cognitive control in functional dissociative seizures?","volume":"179","author":"Chupin","year":"2023","journal-title":"Med. Hypotheses"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2406285","DOI":"10.1080\/24740527.2024.2406285","article-title":"Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial","volume":"8","author":"Lee","year":"2024","journal-title":"Can. J. Pain"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Jones, G.M., Ricard, J.A., and Nock, M.K. (2024). Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension. Front. Psychiatry, 15.","DOI":"10.3389\/fpsyt.2024.1169686"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/eat.24041","article-title":"\u201cBut the reality is it\u2019s happening\u201d: A qualitative study of eating disorder providers about psilocybin-assisted psychotherapy","volume":"56","author":"Downey","year":"2023","journal-title":"Int. J. Eat. Disord."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Earleywine, M., Mian, M.N., and De Leo, J.A. (2023). Expectancies for Subjective and Antidepressant Effects in Psilocybin Users. J. Humanist. Psychol.","DOI":"10.1177\/00221678231194798"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1017\/S0033291723003653","article-title":"Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression","volume":"54","author":"Szigeti","year":"2024","journal-title":"Psychol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2147\/DDDT.S443177","article-title":"The Promise of Therapeutic Psilocybin: An Evaluation of the 134 Clinical Trials, 54 Potential Indications, and 0 Marketing Approvals on ClinicalTrials.gov","volume":"18","author":"Norring","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/02698811231167848","article-title":"A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression","volume":"37","author":"Weiss","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ajp.2016.08.010","article-title":"Return of the psychedelics: Psilocybin for treatment resistant depression","volume":"24","author":"Patra","year":"2016","journal-title":"Asian J. Psychiatry"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"De la Salle, S., Kettner, H., Thibault Levesque, J., Garel, N., Dames, S., Patchett-Marble, R., Rej, S., Gloeckler, S., Erritzoe, D., and Carhart-Harris, R. (2024). Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-66817-0"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/2666082218666220513142002","article-title":"The Efficacy of Psilocybin in the Treatment of Depression and Anxiety: A Meta-Analysis","volume":"19","author":"Hodge","year":"2023","journal-title":"Curr. Psychiatry Res. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e066019","DOI":"10.1136\/bmjopen-2022-066019","article-title":"Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: Protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)","volume":"12","author":"Jensen","year":"2022","journal-title":"BMJ Open"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/02698811221131997","article-title":"Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of \u2018magic mushroom\u2019 consumption","volume":"37","author":"Morton","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/0022167816673493","article-title":"Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism","volume":"57","author":"Bogenschutz","year":"2017","journal-title":"J. Humanist. Psychol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Hibicke, M., and Nichols, C.D. (2022). Validation of the forced swim test in Drosophila, and its use to demonstrate psilocybin has long-lasting antidepressant-like effects in flies. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-14165-2"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/s41386-020-0694-z","article-title":"Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse","volume":"45","author":"Meinhardt","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ymben.2019.09.009","article-title":"In vivo production of psilocybin in E. coli","volume":"56","author":"Adams","year":"2019","journal-title":"Metab. Eng."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"8281","DOI":"10.1002\/chem.202000134","article-title":"Scalable Hybrid Synthetic\/Biocatalytic Route to Psilocybin","volume":"26","author":"Fricke","year":"2020","journal-title":"Chemistry"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/IntJMedMushrooms.2021041921","article-title":"Psilocybin Conspectus: Status, Production Methods, and Considerations","volume":"24","author":"Plotnik","year":"2022","journal-title":"Int. J. Med. Mushrooms"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Rucker, J.J., and Young, A.H. (2021). Psilocybin: From Serendipity to Credibility?. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.659044"},{"key":"ref_99","first-page":"1","article-title":"Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts","volume":"56","author":"Hoffman","year":"2024","journal-title":"J. Psychoact. Drugs"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.17151\/culdr.2023.28.35.4","article-title":"Psilocybin, fashionable therapy for the Google world","volume":"35","author":"Fericgla","year":"2023","journal-title":"Cult. Droga"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/0004867419888575","article-title":"Psilocybin-assisted therapy for depression: How do we advance the field?","volume":"54","author":"Meikle","year":"2020","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/s41380-024-02575-9","article-title":"Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: Contributions from 5-HT1A and 5-HT2A receptor mechanisms","volume":"29","author":"Conn","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"109504","DOI":"10.1016\/j.neuropharm.2023.109504","article-title":"Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders","volume":"231","author":"Wulff","year":"2023","journal-title":"Neuropharmacology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s13063-024-08268-6","article-title":"Engaging Mood Brain Circuits with Psilocybin (EMBRACE): A study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression","volume":"25","author":"Poulin","year":"2024","journal-title":"Trials"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/02698811241237870","article-title":"Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression","volume":"38","author":"Erritzoe","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1021\/acsomega.1c06708","article-title":"Psilocybin: Characterization of the Metastable Zone Width (MSZW), Control of Anhydrous Polymorphs, and Particle Size Distribution (PSD)","volume":"7","author":"Kargbo","year":"2022","journal-title":"ACS Omega"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1107\/S2053229621013164","article-title":"Psilocybin: Crystal structure solutions enable phase analysis of prior art and recently patented examples","volume":"78","author":"Sherwood","year":"2022","journal-title":"Acta Crystallogr. C Struct. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ymben.2019.12.007","article-title":"Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives","volume":"60","author":"Milne","year":"2020","journal-title":"Metab. Eng."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1037\/scp0000242","article-title":"Spiritual Experiences in Psychedelic-Assisted Psychotherapy: Case Reports of Communion with the Divine, the Departed, and Saints in Research Using Psilocybin for the Treatment of Alcohol Dependence","volume":"8","author":"Podrebarac","year":"2021","journal-title":"Spiritual. Clin. Pract."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/4\/555\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:11:41Z","timestamp":1760029901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/4\/555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":109,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["ph18040555"],"URL":"https:\/\/doi.org\/10.3390\/ph18040555","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]}}}